Profiling ALS Immunity Using ProteomeLab PF 2D
Author Information
Author(s): Joshua D Schlautman, Wojciech Rozek, Robert Stetler, R Lee Mosley, Howard E Gendelman, Pawel Ciborowski
Primary Institution: University of Nebraska Medical Center
Hypothesis
The study investigates plasma proteome changes in ALS patients before and during immunization with glatiramer acetate.
Conclusion
The ProteomeLab PF 2D platform shows promise for protein profiling and biomarker discovery in ALS.
Supporting Evidence
- The study utilized a novel proteomic platform to analyze plasma samples.
- Immunoaffinity depletion was used to remove the most abundant proteins from plasma.
- The platform allows for high sensitivity in protein identification.
Takeaway
This study looks at how proteins in the blood of ALS patients change when they receive a specific treatment, helping us understand the disease better.
Methodology
The study used multidimensional protein fractionation, including immunoaffinity depletion and various chromatography techniques, to analyze plasma samples from ALS patients.
Limitations
The study has limitations related to the low throughput of the PF 2D platform and the potential masking of differential protein expression.
Participant Demographics
Plasma samples were collected from 3 ALS patients treated with glatiramer acetate.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website